share_log

Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $17

Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $17

Canaccord Genuity 维持对AngioDynamics的买入,将目标价下调至17美元
Benzinga ·  2023/10/05 14:30

Canaccord Genuity analyst William Plovanic maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers the price target from $20 to $17.

Canaccel Genuity分析师威廉·普洛瓦尼奇维持AngioDynamic(纳斯达克:ANGO)的买入,并将目标价从20美元下调至17美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发